Vivo Capital LLC Purchases Shares of 510,204 Silence Therapeutics plc (NASDAQ:SLN)

Vivo Capital LLC bought a new position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 510,204 shares of the company's stock, valued at approximately $8,862,000. Silence Therapeutics makes up about 0.7% of Vivo Capital LLC's holdings, making the stock its 28th biggest position. Vivo Capital LLC owned about 1.70% of Silence Therapeutics as of its most recent SEC filing.

Separately, SG Americas Securities LLC bought a new position in shares of Silence Therapeutics in the fourth quarter worth $110,000. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, March 15th. BMO Capital Markets began coverage on Silence Therapeutics in a report on Wednesday, January 31st. They issued an "outperform" rating and a $67.00 target price on the stock. Morgan Stanley reissued an "overweight" rating and set a $45.00 price target on shares of Silence Therapeutics in a report on Monday, April 22nd. Finally, Chardan Capital lifted their target price on Silence Therapeutics from $26.00 to $42.00 and gave the company a "buy" rating in a research report on Thursday, March 14th.

Silence Therapeutics Price Performance

Shares of NASDAQ:SLN traded up $0.35 during trading on Thursday, hitting $22.95. 189,822 shares of the company were exchanged, compared to its average volume of 226,768. Silence Therapeutics plc has a 1-year low of $4.84 and a 1-year high of $27.72. The company has a market capitalization of $686.89 million, a P/E ratio of -16.29 and a beta of 1.38. The company has a quick ratio of 4.56, a current ratio of 4.56 and a debt-to-equity ratio of 0.01. The business's 50 day moving average is $22.67 and its 200-day moving average is $18.33.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.22). Silence Therapeutics had a negative return on equity of 262.17% and a negative net margin of 171.41%. The firm had revenue of $2.61 million during the quarter, compared to analyst estimates of $11.46 million. Equities analysts forecast that Silence Therapeutics plc will post -1.38 earnings per share for the current year.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.